Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 8/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22985399 | 0.96 | KIF11 (0.34) | KIF11ARNSD2TRPV4AKR1C3 | |
| SCHEMBL22985089 | 0.96 | KIF11 (0.34) | KIF11ARNSD2TRPV4AKR1C3 | |
| SCHEMBL22985268 | 0.95 | AR (0.35) | KIF11ARNSD2SYK | |
| SCHEMBL20849069 | 0.94 | KIF11 (0.34) | KIF11ARNSD2ELANE | |
| SCHEMBL22985003 | 0.93 | AR (0.43) | KIF11ARNSD2TRPV4AKR1C3 | |
| SCHEMBL22985423 | 0.92 | AR (0.46) | KIF11ARNSD2SYKCYP11B2 | |
| SCHEMBL22985011 | 0.92 | KIF11 (0.36) | KIF11ARNSD2TRPV4AKR1C3 | |
| SCHEMBL22985326 | 0.92 | AR (0.34) | KIF11ARNSD2SYK | |
| SCHEMBL22985098 | 0.92 | AR (0.34) | KIF11ARNSD2SYK | |
| SCHEMBL22985271 | 0.91 | AR (0.34) | KIF11ARNSD2TRPV4AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919880-B2 | Organic molecules, in particular for use in optoelectronic devices | CYNORA GMBH (DE) | 2021-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919880-B2 | Organic molecules, in particular for use in optoelectronic devices | OCIAD1, OCIAD2, POU2F1 | KIF11 525/4885AR 3541/4885NSD2 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.